PhD, BCMAS Chair, Accreditation Council for Medical Affairs
MD Head of Operations, South America
MD, BCMAS Chief Scientific Officer, Accreditation Council for Medical Affairs
PharmD Head of Operations, Middle East/EMEA Region
Dr. William Soliman is a seasoned executive with several years of experience in the pharmaceutical and biotechnology industry. He has held several key positions where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry. He is often invited to speak at important pharmaceutical industry conferences focusing on medical affairs, patient navigation and its relationship to field based medical teams, and the ever-changing role of the medical science liaison (MSL). He has a wide range of experience holding a variety of critical management roles across the industry at companies such as Retrophin, Veeva Systems, Eisai, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim and Merck. Dr. Soliman previously also served as Vice President of Medical and Scientific Affairs at CME LLC, a leading provider of CME to healthcare providers nationwide.
He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes and obesity, and has collaborated with some of the nation’s top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania’s Center for Weight & Eating Disorders. Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy’s (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among pre-diabetic overweight and obese individuals. Dr. Soliman has also held several academic appointments at Seton Hall University’s School of Health & Medical Sciences, New Jersey City University, Kean University’s College of Natural & Applied Sciences, and Touro Colleges of Osteopathic Medicine, Pharmacy & Physical Therapy, teaching a variety of courses, including clinical therapeutics, pharmacology, pathophysiology and epidemiology. Dr. Soliman earned his Ph.D., MPhil from Columbia University, his bachelor’s degree from New York University and his master’s degree from St. Peter’s University. Dr. Soliman has served as a board member for the MSL Institute. He is a member of several organizations including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), and the Drug Information Association (DIA), and he is a life sciences consultant board member at GLG consulting and the American Chemical Society (ACS).
Charles Schmidt is a trained Pediatrician with Master and Doctorate degree. He has been practicing and teaching while working in the biopharma for the past 25 years. He had developed and managed successfully big and mediun size CROs in Latin America and at their global level for more than 15 years. His experience also includes leadership roles in Medical Affairs, Pharmacovigilance, and Medical Monitoring in Pharmaceutical companies. Charles has an extensive background in clinical development efforts in many therapeutic areas in LatAm. He is an attending physician in coordinating the post-graduation program in clinical research at Santa Casa Medical School in Sao Paulo – Brazil since 2007. Also, he is the medical manager of the central institute of clinical research at Hospital de Clínicas – Sao Paulo. Charles was the founder and ex-president of the Brazilian Association of CROs and member and ex-director of Brazilian Association of Pharmaceutical Physicians – SBMF.
Ahmed is a Clinical Research Scientist with several years of experience across Europe, US and in the Middle East. He has have extensive experience in Clinical Data Management, Project Management, Medical Writing, Health Economics and Outcomes Research. He has worked with several CROs, Hospitals and within the pharmaceutical industry. He holds a Bachelor of Pharmaceutical Sciences and a Pharm.D from the University of Colorado. Ahmed’s leads effort to increase awareness of our mission and goals in the Middle East/ EMEA region.
MD, BCMAS Chief Scientific Officer Accreditation Council for Medical Affairs
Dr. Rowe has well over a decade of research experience spanning from pre-clinical to late phase drug development programs, primarily in respiratory (and cardiovascular) medicine. He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma, and cardiovascular medicines. Dr. Rowe has been successfully involved in achieving New Drug Application (NDA) approvals for first in therapeutic class respiratory products and also has led various clinical development global projects from phase II through phase IV clinical trials. He has authored and co-authored several publications in respiratory medicine (COPD-focused, and is a frequent lecturer and speaker at professional society meetings, and educational forums. Dr. Rowe holds degrees from Harvard University and the University of Rochester School of Medicine, and certifications from the London School of Economics and Villanova University.
Dr. Rowe is an active member of several national and international societies and he recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS). He has a primary interest in promoting international medical research collaboration and innovation across government, academia, and industry.
In his current role, Dr. Rowe is responsible for building and leading a Global Medical Affairs team and strategy within the respiratory space for several novel compounds in mid and late stage development, in various therapeutic indications.